Verve Financial Statements From 2010 to 2026

VERVDelisted Stock  USD 11.13  0.00  0.00%   
Verve Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Verve Therapeutics' valuation are provided below:
Verve Therapeutics does not presently have any fundamental trend indicators for analysis.
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Verve Therapeutics Company Return On Equity Analysis

Verve Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Verve Therapeutics Return On Equity

    
  -0.34  
Most of Verve Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verve Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Verve Therapeutics has a Return On Equity of -0.3426. This is 98.57% lower than that of the Biotechnology sector and 99.06% lower than that of the Health Care industry. The return on equity for all United States stocks is 10.52% higher than that of the company.

Verve Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Verve Therapeutics's current stock value. Our valuation model uses many indicators to compare Verve Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verve Therapeutics competition to find correlations between indicators driving Verve Therapeutics's intrinsic value. More Info.
Verve Therapeutics is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Verve Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Consideration for investing in Verve Stock

If you are still planning to invest in Verve Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Verve Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios